{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:52:12Z","timestamp":1784854332994,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Retinal vein occlusion (RVO) is a prevalent retinal vascular disorder characterized by retinal haemorrhage, neovascularization, and macular edema This study aimed to assess the structural and functional effects of intravitreal implant (Ozurdex) treatment as a second-line for RVO-associated macular edema in patients who did not respond to first-line anti-VEGF therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>We conducted a retrospective observational cohort study using electronic health records of RVO patients at Salisbury District Hospital between January 2014 and December 2019. Inclusion criteria included patients diagnosed with central or branch RVO. Patients underwent ophthalmic evaluations at baseline, including central retinal thickness (CRT) and best-corrected visual acuity (BCVA) assessments. Statistical analysis was performed using IBM SPSS Statistics, employing various tests to determine significance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Sixteen eyes of 16 White British patients were evaluated. Most patients had branch RVO (52.95%), and 47.05% had central RVO. While anti-VEGF treatment significantly improved BCVA (<jats:italic>p<\/jats:italic>\u2009=\u20090.0061), Ozurdex did not result in additional gain (<jats:italic>p<\/jats:italic>\u2009=\u20090.747). Both treatments significantly reduced CRT (<jats:italic>p<\/jats:italic>\u2009=\u20090.0055 for anti-VEGF; <jats:italic>p<\/jats:italic>\u2009=\u20090.0079 for Ozurdex). No significant differences were observed between diabetic and non-diabetic BCVA patients receiving either treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Ozurdex emerges as a safe and effective option for persistent macular edema in RVO patients unresponsive to anti-VEGF therapy. Although structural improvements in CRT were observed following Ozurdex treatment, they did not correlate with additional gain in BCVA. Despite this, the reduced treatment frequency of Ozurdex compared to anti-VEGF injections may be advantageous, particularly for frail non-responding patients minimizing treatment burden.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11845-025-03881-z","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T06:59:20Z","timestamp":1737701960000},"page":"745-750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Ozurdex implants as second-line therapy for non-responders to anti-VEGF in retinal vein occlusion-associated macular edema: a retrospective cohort study"],"prefix":"10.1007","volume":"194","author":[{"given":"Mahmoud","family":"Eissa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Kalogeropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashi","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5541-4305","authenticated-orcid":false,"given":"Andrew John","family":"Lotery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"3881_CR1","first-page":"188","volume":"29","author":"S Fuma","year":"2023","unstructured":"Fuma S, Hidaka Y, Nishinaka A and others (2023) Timolol maleate, a \u03b2 blocker eye drop, improved edema in a retinal vein occlusion model. Mol Vis 29:188\u2013196","journal-title":"Mol Vis"},{"key":"3881_CR2","doi-asserted-by":"publisher","first-page":"e23716","DOI":"10.1016\/j.heliyon.2023.e23716","volume":"10","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang Y, Yong H and others (2024) Biochemical and microstructural determinants of the development of serous retinal detachment secondary to retinal vein occlusion. Heliyon 10:e23716. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23716","journal-title":"Heliyon"},{"key":"3881_CR3","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/IAE.0000000000003769","volume":"43","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Matsumoto H, Barakat MR and others (2023) Retinal vasculitis or vascular occlusion after brolucizumab for neovascular age-related macular degeneration. Retina Phila Pa 43:1051\u20131063. https:\/\/doi.org\/10.1097\/IAE.0000000000003769","journal-title":"Retina Phila Pa"},{"key":"3881_CR4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41433-022-02007-4","volume":"36","author":"L Nicholson","year":"2022","unstructured":"Nicholson L, Talks SJ, Amoaku W and others (2022) Retinal vein occlusion (RVO) guideline: executive summary. Eye 36:909\u2013912. https:\/\/doi.org\/10.1038\/s41433-022-02007-4","journal-title":"Eye"},{"key":"3881_CR5","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.18240\/ijo.2023.12.18","volume":"16","author":"L Tang","year":"2023","unstructured":"Tang L, Sun G-L, Zhao Y and others (2023) Optical coherence tomography angiography for macular microvessels in ischemic branch retinal vein occlusion treated with conbercept: predictive factors for the prognosis. Int J Ophthalmol 16:2049\u20132055. https:\/\/doi.org\/10.18240\/ijo.2023.12.18","journal-title":"Int J Ophthalmol"},{"key":"3881_CR6","doi-asserted-by":"publisher","first-page":"e36512","DOI":"10.1097\/MD.0000000000036512","volume":"102","author":"MB \u00dc\u00e7er","year":"2023","unstructured":"\u00dc\u00e7er MB, Cevher S (2023) Assessment of systemic inflammatory response index and other inflammatory indicators in retinal vein occlusion. Med (Baltimore) 102:e36512. https:\/\/doi.org\/10.1097\/MD.0000000000036512","journal-title":"Med (Baltimore)"},{"key":"3881_CR7","doi-asserted-by":"publisher","first-page":"100418","DOI":"10.1016\/j.xops.2023.100418","volume":"4","author":"D Nagasato","year":"2024","unstructured":"Nagasato D, Muraoka Y, Tanabe M and others (2024) Foveal thickness fluctuations in anti-VEGF treatment for central retinal vein occlusion. Ophthalmol Sci 4:100418. https:\/\/doi.org\/10.1016\/j.xops.2023.100418","journal-title":"Ophthalmol Sci"},{"key":"3881_CR8","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/healthcare11101414","volume":"11","author":"D-M Darabu\u015f","year":"2023","unstructured":"Darabu\u015f D-M, Munteanu M, Preda M-A and others (2023) The impact of intraocular treatment on visual acuity of patients diagnosed with branch retinal vein occlusions. Healthc Basel Switz 11:1414. https:\/\/doi.org\/10.3390\/healthcare11101414","journal-title":"Healthc Basel Switz"},{"key":"3881_CR9","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1167\/iovs.18-26383","volume":"60","author":"N Patel","year":"2019","unstructured":"Patel N, Stirrup S (2019) Clinical outcomes in primary and secondary Ozurdex therapy for macular oedema in retinal vein occlusion. Invest Ophthalmol Vis Sci 60:2557","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3881_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2174\/1573399811666150615151324","volume":"17","author":"C Campa","year":"2016","unstructured":"Campa C, Alivernini G, Bolletta E and others (2016) Anti-VEGF therapy for retinal vein occlusions. Curr Drug Targets 17:328\u2013336. https:\/\/doi.org\/10.2174\/1573399811666150615151324","journal-title":"Curr Drug Targets"},{"key":"3881_CR11","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.2147\/PPA.S427209","volume":"17","author":"A Taloni","year":"2023","unstructured":"Taloni A, Coco G, Rastelli D and others (2023) Safety and efficacy of dexamethasone intravitreal implant given either first-line or second-line in diabetic macular edema. Patient Prefer Adherence 17:3307\u20133329. https:\/\/doi.org\/10.2147\/PPA.S427209","journal-title":"Patient Prefer Adherence"},{"key":"3881_CR12","doi-asserted-by":"publisher","first-page":"989501","DOI":"10.1155\/2014\/989501","volume":"2014","author":"V Sarao","year":"2014","unstructured":"Sarao V, Veritti D, Boscia F, Lanzetta P (2014) Intravitreal steroids for the treatment of retinal diseases. Sci World J 2014:989501. https:\/\/doi.org\/10.1155\/2014\/989501","journal-title":"Sci World J"},{"key":"3881_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.14744\/bej.2019.63835","volume":"4","author":"E Eris","year":"2019","unstructured":"Eris E, Perente I, Erdogan G and others (2019) Clinical use of dexamethasone implants in resistant macular edema secondary to branch retinal vascular occlusion compared with intravitreal anti-vascular endothelial growth factor. Beyoglu Eye J 4:11\u201316. https:\/\/doi.org\/10.14744\/bej.2019.63835","journal-title":"Beyoglu Eye J"},{"key":"3881_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1167\/iovs.10-5285","volume":"52","author":"J-E Chang-Lin","year":"2011","unstructured":"Chang-Lin J-E, Attar M, Acheampong AA and others (2011) Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 52:80\u201386. https:\/\/doi.org\/10.1167\/iovs.10-5285","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3881_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","volume":"129","author":"C Lowder","year":"2011","unstructured":"Lowder C, Belfort R Jr, Lightman S and others (2011) Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 129:545\u2013553. https:\/\/doi.org\/10.1001\/archophthalmol.2010.339","journal-title":"Arch Ophthalmol"},{"key":"3881_CR16","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1167\/iovs.12-11463","volume":"54","author":"M Dutra Medeiros","year":"2013","unstructured":"Dutra Medeiros M, Navarro R, Garcia-Arum\u00ed J and others (2013) Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from irvine-gass syndrome. Invest Ophthalmol Vis Sci 54:3320\u20133324. https:\/\/doi.org\/10.1167\/iovs.12-11463","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3881_CR17","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s00417-012-2249-4","volume":"251","author":"M Srour","year":"2013","unstructured":"Srour M, Querques G, Leveziel N and others (2013) Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 251:1501\u20131506. https:\/\/doi.org\/10.1007\/s00417-012-2249-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3881_CR18","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer DS, Yoon YH, Belfort R and others (2014) Three-Year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121:1904\u20131914. https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.024","journal-title":"Ophthalmology"},{"key":"3881_CR19","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","volume":"117","author":"JA Haller","year":"2010","unstructured":"Haller JA, Bandello F, Belfort R and others (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134-1146.e3. https:\/\/doi.org\/10.1016\/j.ophtha.2010.03.032","journal-title":"Ophthalmology"},{"key":"3881_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/ceo.14225","volume":"51","author":"EE Cornish","year":"2023","unstructured":"Cornish EE, Zagora SL, Spooner K, Fraser-Bell S (2023) Management of macular oedema due to retinal vein occlusion: an evidence-based systematic review and meta-analysis. Clin Experiment Ophthalmol 51:313\u2013338. https:\/\/doi.org\/10.1111\/ceo.14225","journal-title":"Clin Experiment Ophthalmol"},{"key":"3881_CR21","first-page":"3890","volume":"55","author":"V Juniat","year":"2014","unstructured":"Juniat V, Tsolakou E, Patel N (2014) Ozurdex outcomes in retinal vein occlusion (RVO) with macular oedema (MO). Invest Ophthalmol Vis Sci 55:3890","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3881_CR22","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2147\/OPTH.S241044","volume":"14","author":"F Horner","year":"2020","unstructured":"Horner F, Lip PL, Mushtaq B and others (2020) Combination therapy for macular oedema in retinal vein occlusions: 3-year results from a real-world clinical practice. Clin Ophthalmol 14:955\u2013965. https:\/\/doi.org\/10.2147\/OPTH.S241044","journal-title":"Clin Ophthalmol"},{"key":"3881_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/eye.2012.226","volume":"27","author":"E Moisseiev","year":"2013","unstructured":"Moisseiev E, Goldstein M, Waisbourd M and others (2013) Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye 27:65\u201371. https:\/\/doi.org\/10.1038\/eye.2012.226","journal-title":"Eye"},{"key":"3881_CR24","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","volume":"118","author":"JA Haller","year":"2011","unstructured":"Haller JA, Bandello F, Belfort R and others (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118:2453\u20132460. https:\/\/doi.org\/10.1016\/j.ophtha.2011.05.014","journal-title":"Ophthalmology"},{"key":"3881_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/OPTH.S15783","volume":"5","author":"R Herrero-Vanrell","year":"2011","unstructured":"Herrero-Vanrell R, Cardillo JA, Kuppermann BD (2011) Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol Auckl NZ 5:139\u2013146. https:\/\/doi.org\/10.2147\/OPTH.S15783","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"3881_CR26","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2147\/OPTH.S13775","volume":"5","author":"A Chan","year":"2011","unstructured":"Chan A, Leung L-S, Blumenkranz MS (2011) Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion. Clin Ophthalmol Auckl NZ 5:1043\u20131049. https:\/\/doi.org\/10.2147\/OPTH.S13775","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"3881_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000364956","volume":"232","author":"E Maggio","year":"2014","unstructured":"Maggio E, Polito A, Guerriero M, Pertile G (2014) Intravitreal dexamethasone implant for macular edema secondary to retinal vein occlusion: 12-month follow-up and prognostic factors. Ophthalmologica 232:207\u2013215. https:\/\/doi.org\/10.1159\/000364956","journal-title":"Ophthalmologica"},{"key":"3881_CR28","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00417-015-2947-9","volume":"253","author":"C Chiquet","year":"2015","unstructured":"Chiquet C, Dupuy C, Bron AM and others (2015) Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-na\u00efve patients with retinal vein occlusion and macular edema: a 12-month follow-up study. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol 253:2095\u20132102. https:\/\/doi.org\/10.1007\/s00417-015-2947-9","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"key":"3881_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2174\/1574886309666140805142245","volume":"10","author":"I Tservakis","year":"2015","unstructured":"Tservakis I, Koutsandrea C, Papaconstantinou D and others (2015) Safety and efficacy of dexamethasone intravitreal implant (Ozurdex) for the treatment of persistent macular edema secondary to retinal vein occlusion in eyes previously treated with anti-vascular endothelial growth factors. Curr Drug Saf 10:145\u2013151","journal-title":"Curr Drug Saf"},{"key":"3881_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12886-022-02415-w","volume":"22","author":"V Castro-Navarro","year":"2022","unstructured":"Castro-Navarro V, Monferrer-Adsuara C, Navarro-Palop C and others (2022) Optical coherence tomography biomarkers in patients with macular edema secondary to retinal vein occlusion treated with dexamethasone implant. BMC Ophthalmol 22:191. https:\/\/doi.org\/10.1186\/s12886-022-02415-w","journal-title":"BMC Ophthalmol"},{"key":"3881_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00417-017-3831-6","volume":"256","author":"X Li","year":"2018","unstructured":"Li X, Wang N, Liang X and others (2018) Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. Graefes Arch Clin Exp Ophthalmol 256:59\u201369. https:\/\/doi.org\/10.1007\/s00417-017-3831-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3881_CR32","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1111\/aos.12020","volume":"91","author":"A Bezatis","year":"2013","unstructured":"Bezatis A, Spital G, H\u00f6hn F and others (2013) Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up\u2013the SOLO study. Acta Ophthalmol (Copenh) 91:e340\u2013e347. https:\/\/doi.org\/10.1111\/aos.12020","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"3881_CR33","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.ophtha.2011.12.028","volume":"119","author":"W-S Yeh","year":"2012","unstructured":"Yeh W-S, Haller JA, Lanzetta P and others (2012) Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology 119:1190\u20131198. https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.028","journal-title":"Ophthalmology"},{"key":"3881_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00417-016-3431-x","volume":"255","author":"N Eter","year":"2017","unstructured":"Eter N, Mohr A, Wachtlin J and others (2017) Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol 255:77\u201387. https:\/\/doi.org\/10.1007\/s00417-016-3431-x","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"key":"3881_CR35","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1097\/IAE.0000000000001004","volume":"36","author":"RK Maturi","year":"2016","unstructured":"Maturi RK, Pollack A, Uy HS and others (2016) Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year mead study. Retina Phila Pa 36:1143\u20131152. https:\/\/doi.org\/10.1097\/IAE.0000000000001004","journal-title":"Retina Phila Pa"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-03881-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-025-03881-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-03881-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:14:49Z","timestamp":1745561689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-025-03881-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3881"],"URL":"https:\/\/doi.org\/10.1007\/s11845-025-03881-z","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"16 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}